Charu Aggarwal, MD, MPH

Articles

Intracranial Efficacy of Datopotamab Deruxtecan in Patients With Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From TROPION-Lung05

June 27th 2024

Tropion-Lung05 (NCT04484142) is a phase 2, multicenter, single-arm, open-label study evaluating Dato-DXd in patients with advanced/metastatic NSCLC with actionable genomic alterations who have progressed on or after targeted therapy and platinum-based CT.

Advancement in Treating Uncommon EGFR Mutations: Key Takeaways

January 3rd 2024

Discover the latest insights on treating uncommon EGFR mutations, emphasizing the importance of NGS, personalized therapy, and ongoing advancements in TKIs and ADCs.

Investigational Avenues in Uncommon EGFR Mutations: NSCLC Treatment Insight

December 27th 2023

Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.

UNICORN Study: Osimertinib and Other Emerging Treatments for Uncommon EGFR Mutations

December 27th 2023

Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.

Navigating Post-Afatinib Progression: Treatment Sequencing Strategies in NSCLC

December 20th 2023

Expert insights on sequencing treatment options for patients with uncommon EGFR mutations who have progressed on afatinib, emphasizing clinical trial considerations, biomarker testing, and emerging therapeutic approaches.

Optimizing Afatinib Use: Dosing Strategies and Adverse Event Management

December 20th 2023

Explore dosing nuances and adverse event management strategies for afatinib in treating EGFR mutant non-small cell lung cancer, reflecting real-world practices and clinical insights.

Treatment Strategies for Uncommon EGFR Mutations in NSCLC

December 13th 2023

Panelists discuss the intricacies of treating uncommon EGFR mutations, dissecting approved treatment options, considerations for specific mutations, and insights into the evolving drug landscape.

Navigating Uncommon EGFR Mutations in NSCLC: Challenges and Insights

December 13th 2023

Explore the complexity of uncommon EGFR mutations in lung cancer with experts discussing classifications, testing methodologies, and the necessity of comprehensive panels for accurate identification.

Advancements in Targeted Therapy for Metastatic NSCLC

December 11th 2023

Shared insight into the transformative impact of targeted therapies in lung cancer treatment, from adjuvant therapy breakthroughs to emerging trials, emphasizing the critical role of comprehensive molecular testing.

Metastatic NSCLC: Key Challenges in Molecular Testing and Treatment Access

December 11th 2023

Explore the complexities of limited molecular genotyping availability, the importance of comprehensive testing, and challenges in accessing target therapies, including cost considerations, in real-world clinical practice.

Standard-of-Care Approaches in EGFR-Mutant NSCLC

December 6th 2023

Delve into the evolving landscape of treating EGFR mutations in lung cancer, exploring emerging therapies, structural classifications, and the complexity of individual mutation responses.

Navigating Uncommon Mutations in NSCLC Treatment Decisions

December 6th 2023

The impact of and strategies for addressing less frequent mutations in NSCLC treatment decisions, emphasizing actionable alterations and timely interventions in challenging scenarios.

Barriers in Concurrent Testing for mNSCLC: Real-world Challenges and Solutions

December 4th 2023

Experts reflect on the mixed enthusiasm for concurrent liquid and tissue testing, addressing insurance coverage concerns and the importance of shortening turnaround time, while highlighting efforts to make comprehensive testing the default in the community.

Impact of Molecular Testing on Lung Cancer Survival: Real-world Insights

December 4th 2023

A comprehensive study on the association between the availability of molecular genotyping results and overall survival in advanced non-squamous, non-small cell lung cancer patients, shedding light on the importance of timely and concurrent testing.

Non–Small Cell Lung Cancer: Streamlining Turnaround Times in Biomarker Testing

November 29th 2023

Expert perspectives on improving turnaround times in genomic testing for lung cancer, covering strategies, challenges, and the significance of liquid biopsy in optimizing patient care.

Available Methods for Biomarker Testing in Non–Small Cell Lung Cancer

November 29th 2023

Shared insight into strategies in genomic testing for lung cancer, emphasizing the importance of comprehensive next-generation sequencing, DNA vs. RNA sequencing, and the evolving role of liquid biopsy.

Decoding Lung Cancer Mutations: Navigating Molecular Profiling in Practice

November 27th 2023

Key opinion leaders Charu Aggarwal, MD, MPH, and Melina E. Marmarelis, MD, reflect on their institution’s practices with regard to molecular profiling and its impact on treatment pathways in the setting of metastatic NSCLC.

Identifying Key Molecular Targets in Metastatic NSCLC

November 27th 2023

Shared insight into the comprehensive list of molecular targets in metastatic NSCLC, from point mutations like EGFR and KRAS to fusions such as ALK and ROS1, understanding the challenges of comprehensive testing and treatment implications.

Patient Scenario: Navigating Molecular Testing Dilemmas in Metastatic NSCLC

November 20th 2023

Experts review a patient scenario of metastatic non-squamous NSCLC and discuss complexities and challenges of initiating timely molecular testing, examining its impact on treatment decisions and patient outcomes.

Advancements in Precision Oncology: Metastatic NSCLC Treatment Landscape

November 20th 2023

Explore the dynamic landscape of metastatic non-squamous non-small cell lung cancer treatment, focusing on molecular genotyping, targeted therapies, and the evolving standard of care.